Mora Cristina, Serzanti Marialaura, Consiglio Antonella, Memo Maurizio, Dell'Era Patrizia
Cellular Fate Reprogramming Unit, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa, 11, 25123, Brescia, Italy.
Pharmacology Unit, Department of Molecular and Translational Medicine, University of Brescia, 25123, Brescia, Italy.
Cell Biol Toxicol. 2017 Aug;33(4):351-360. doi: 10.1007/s10565-017-9384-y. Epub 2017 Feb 8.
Aging, injuries, and diseases can be considered as the result of malfunctioning or damaged cells. Regenerative medicine aims to restore tissue homeostasis by repairing or replacing cells, tissues, or damaged organs, by linking and combining different disciplines including engineering, technology, biology, and medicine. To pursue these goals, the discipline is taking advantage of pluripotent stem cells (PSCs), a peculiar type of cell possessing the ability to differentiate into every cell type of the body. Human PSCs can be isolated from the blastocysts and maintained in culture indefinitely, giving rise to the so-called embryonic stem cells (ESCs). However, since 2006, it is possible to restore in an adult cell a pluripotent ESC-like condition by forcing the expression of four transcription factors with the rejuvenating reprogramming technology invented by Yamanaka. Then the two types of PSC can be differentiated, using standardized protocols, towards the cell type necessary for the regeneration. Although the use of these derivatives for therapeutic transplantation is still in the preliminary phase of safety and efficacy studies, a lot of efforts are presently taking place to discover the biological mechanisms underlying genetic pathologies, by differentiating induced PSCs derived from patients, and new therapies by challenging PSC-derived cells in drug screening.
衰老、损伤和疾病可被视为细胞功能失调或受损的结果。再生医学旨在通过修复或替换细胞、组织或受损器官来恢复组织稳态,它将工程学、技术、生物学和医学等不同学科联系并结合起来。为实现这些目标,该学科正在利用多能干细胞(PSC),这是一种特殊类型的细胞,具有分化为身体每种细胞类型的能力。人类PSC可从囊胚中分离出来并在培养中无限期维持,从而产生所谓的胚胎干细胞(ESC)。然而,自2006年以来,通过山中伸弥发明的重编程技术强制表达四种转录因子,可使成体细胞恢复到类似多能ESC的状态。然后,使用标准化方案可将这两种类型的PSC分化为再生所需的细胞类型。尽管将这些衍生物用于治疗性移植仍处于安全性和有效性研究的初步阶段,但目前正在付出很多努力,通过分化患者来源的诱导PSC来发现遗传病理学的生物学机制,并在药物筛选中通过挑战PSC衍生细胞来探索新疗法。